Compare RDVT & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDVT | AMPH |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 920.0M | 885.4M |
| IPO Year | 2017 | 2005 |
| Metric | RDVT | AMPH |
|---|---|---|
| Price | $60.86 | $18.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $62.00 | $28.38 |
| AVG Volume (30 Days) | 172.3K | ★ 421.7K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.00 | N/A |
| EPS | ★ 0.30 | 0.14 |
| Revenue | $90,252,000.00 | ★ $719,887,000.00 |
| Revenue This Year | $16.31 | $6.90 |
| Revenue Next Year | $13.83 | $4.64 |
| P/E Ratio | $198.57 | ★ $134.79 |
| Revenue Growth | ★ 20.03 | N/A |
| 52 Week Low | $33.40 | $16.65 |
| 52 Week High | $69.65 | $31.26 |
| Indicator | RDVT | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 48.27 | 44.70 |
| Support Level | $51.49 | $18.92 |
| Resistance Level | $64.14 | $19.99 |
| Average True Range (ATR) | 2.61 | 0.69 |
| MACD | -1.19 | -0.06 |
| Stochastic Oscillator | 27.10 | 27.58 |
Red Violet Inc builds proprietary technologies and applies analytical capabilities to deliver identity intelligence. The company's solutions enable the real-time identification and location of people, businesses, assets, and their interrelationships. These solutions are used for purposes including identity verification, risk mitigation, due diligence, fraud detection and prevention, regulatory compliance, and customer acquisition. Its cloud-native, AI-enabled identity intelligence platform, CORE, is purpose-built for the enterprise, yet flexible enough for organizations of all sizes, bringing clarity to massive datasets by transforming data into intelligence. The company generates substantially all of its revenue from licensing its solutions.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.